Results 181 to 190 of about 19,815 (203)

[Two Ph chromosome positive chronic myelogenous leukemia patients with rare bcr/abl fusion gene].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2008
To investigate the unusual bcr/abl fusion gene structures of two Ph chromosome positive chronic myelogenous leukemia (CML) patients in chronic phase (CP).By using general M- and micro -bcr/abl specific primers respectively, bcr/abl fusion transcripts were detected by reverse transcription-polymerase chain reaction (RT-PCR).
Ya-zhen, Qin, Yan-rong, Liu, Jin-lan, Li, Hui, Wang, Yan, Chang, Jia-yu, Fu, Guo-rui, Ruan, Hui-lin, Shi, Jing-ying, Qiu, Dao-pei, Lu, Shan-shan, Chen   +10 more
openaire   +2 more sources

Cytogenetic profile of 1,863 Ph/BCR-ABL-positive chronic myelogenous leukemia patients from the Chinese population

Annals of Hematology, 2012
Cytogenetic analyses of chronic myelogenous leukemia (CML) have been performed previously in a large number of reports, but systematical research based on large sample sizes from the Chinese population is seldom available. In this study, we analyzed the cytogenetic profiles of 1,863 Philadelphia (Ph)/BCR-ABL-positive CML patients from a research center
Qitian, Mu, Qiuling, Ma, Yungui, Wang, Zhimei, Chen, Xiangmin, Tong, Fei-Fei, Chen, Ying, Lu, Jie, Jin   +7 more
openaire   +2 more sources

Flow cytometric assay of phosphotyrosine levels in Bcr-Abl-positive chronic myelogenous leukemias: a potential prognostic marker

Annals of Hematology, 2008
Assay of phosphotyrosine levels using flow cytometry has been used to identify patients with chronic myelogenous leukemia positive for the Bcr-Abl fusion gene. We hypothesized that clinical monitoring could identify treatment response through reductions in intragranulocyte phosphotyrosine.
Xuemei, Sun, Jianyong, Li, Junhao, Chen, Dong, Li, Leilei, Chen, Wei, Xu, Yonggong, Yang, Yujie, Wu, Pengjun, Jiang, Wei, Xie   +9 more
openaire   +2 more sources

Concomitant JAK2 V617F-Positive Polycythemia Vera and BCR-ABL-Positive Chronic Myelogenous Leukemia Treated with Ruxolitinib and Dasatinib.

Blood, 2012
Abstract Abstract 2832 Co-occurrence of a JAK2 V617F-positive myeloproliferative neoplasm (MPN) with BCR-ABL-positive chronic myelogenous leukemia (CML) in a single patient is rare. Previous reports have suggested that the two disorders may arise independently or within the same clone, but definitive clonal analysis has ...
Eric M. Knoche, Daniel A.C. Fisher, Gregory Rippberger, Li He, Deborah M. Moore, Jonathan L. Klein, Stephen T. Oh   +6 more
openaire   +1 more source

Cytogenetic response to autografting in chronic myelogenous leukemia correlates with the amount of BCR-ABL positive cells in the graft

Experimental Hematology, 2000
An important step in successful autografting of patients with chronic myelogenous leukemia is the delivery of a leukemia-free graft. We conducted this study to determine whether the cytogenetic response after autografting was correlated with the number of BCR ABL-positive cells present within the stem cell grafts.By BCR-ABL mRNA quantification, we ...
M T, Corsetti, E, Lerma, A, Dejana, M, Cavaliere, O, Figari, F, Vassallo, M, Abate, S, Luchetti, G, Piaggio, C, Parodi, G, Li Pira, F, Manca, A M, Carella   +12 more
openaire   +2 more sources

Relationship of the type of bcr-abl hybrid mRNA to clinical course and transforming activity in philadelphia-positive chronic myelogenous leukemia

Leukemia Research, 1992
We studied the type of bcr-abl mRNA for 34 patients with chronic myelogenous leukemia and analyzed for correlations among the mRNA type, the clinical outcome and the transforming activity using the tumorigenicity assay. There was no difference in the distribution of the mRNA-types (b2-a2 and b3-a2) between clinical phases.
M, Futaki, K, Inokuchi, H, Matsuoka, K, Miyake, K, Dan, T, Nomura   +5 more
openaire   +2 more sources

Philadelphia-positive chronic myelogenous leukemia with typical bcr/abl molecular features and atypical, prolonged survival.

Leukemia, 1989
Despite the major breakthrough in the knowledge of the molecular events underlying the t(9;22) translocation, still no consistent data have been found on the evolution of Ph1 positive CML from the chronic to the accelerated or blastic phase of the disease.
Selleri L., Emilia G., Temperani P., Grassilli E., Zucchini P., Tagliafico E., Bonati A., Venezia L., Ferrari S., Torelli U., Torelli G.   +10 more
openaire   +2 more sources

Presence or Re-Appearance of BCR-ABL-Positive Cells Years after Allogeneic Bone Marrow Transplantation for Chronic-Phase Chronic Myelogenous Leukemia in Patients in Hematological Remission

Acta Haematologica, 1994
Allogeneic bone marrow transplantation (BMT) is considered to be the only curative therapy for chronic myelogenous leukemia (CML). The cytogenetic marker of CML, the Philadelphia (Ph) chromosome, or the molecular alterations caused by the BCR-ABL gene fusion can be used to monitor the success of treatment.
L, Diekmann, D W, Beelen, K, Quabeck, R, Becher, H, Schulte Holthausen, R, Bützler, U W, Schaefer, B, Opalka   +7 more
openaire   +2 more sources

Absence of the hybrid bcr‐abl mRNA in Ph¹‐positive B lymphoblastoid cell lines established from a patient with chronic myelogenous leukemia

International Journal of Cancer, 1987
AbstractThe expression of c‐abl, c‐sis, c‐myc and N‐ras oncogenes was examined in 2 lymphoblastoid cell lines, one with Ph1 (PB‐1049) and the other without Ph1 (LN‐1049), both established from a patient with chronic myelogenous leukemia (CML), and in a Ph1‐positive cell line (PB‐1049‐T) derived from a tumor formed after transplantation of PB‐1049 cells
T, Yamada, T, Oikawa, N, Kuzumaki, N, Takagi, M, Sasaki   +4 more
openaire   +2 more sources

Preliminary activity of AMN107, a novel potent oral selective Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP)

Journal of Clinical Oncology, 2006
6591 Background: AMN107 is a novel, highly selective oral Bcr-Abl inhibitor which is 20–50-fold more potent than imatinib. High response rates with AMN107 were observed in all CML phases post imatinib failure. Methods: Study Aims: Evaluate the efficacy of AMN107in newly diagnosed Ph-positive CML-CP.
E. Jabbour, F. Giles, J. Cortes, S. O’Brien, F. Ravandi, G. Borthakur, G. Garcia-Manero, L. Letvak, A. Salvado, H. Kantarjian   +9 more
openaire   +2 more sources